306 related articles for article (PubMed ID: 31751318)
41. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
42. A
Kjaergaard J; Hatfield S; Jones G; Ohta A; Sitkovsky M
J Immunol; 2018 Jul; 201(2):782-791. PubMed ID: 29802128
[TBL] [Abstract][Full Text] [Related]
43. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.
Prévost-Blondel A; Zimmermann C; Stemmer C; Kulmburg P; Rosenthal FM; Pircher H
J Immunol; 1998 Sep; 161(5):2187-94. PubMed ID: 9725210
[TBL] [Abstract][Full Text] [Related]
44. Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade.
Ho WS; Wang H; Maggio D; Kovach JS; Zhang Q; Song Q; Marincola FM; Heiss JD; Gilbert MR; Lu R; Zhuang Z
Nat Commun; 2018 May; 9(1):2126. PubMed ID: 29844427
[TBL] [Abstract][Full Text] [Related]
45. Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells.
Weis-Banke SE; Lisle TL; Perez-Penco M; Schina A; Hübbe ML; Siersbæk M; Holmström MO; Jørgensen MA; Marie Svane I; Met Ö; Ødum N; Madsen DH; Donia M; Grøntved L; Andersen MH
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36316062
[TBL] [Abstract][Full Text] [Related]
46. Deletion of MyD88 in T Cells Improves Antitumor Activity in Melanoma.
Bayer AL; Padilla-Rolon D; Smolgovsky S; Hinds PW; Alcaide P
Am J Pathol; 2024 Jun; 194(6):1007-1019. PubMed ID: 38442804
[TBL] [Abstract][Full Text] [Related]
47. Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapy.
Gough M; Crittenden M; Thanarajasingam U; Sanchez-Perez L; Thompson J; Jevremovic D; Vile R
J Immunol; 2005 May; 174(9):5766-73. PubMed ID: 15843579
[TBL] [Abstract][Full Text] [Related]
48. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.
Li B; Lin J; Vanroey M; Jure-Kunkel M; Jooss K
Clin Immunol; 2007 Oct; 125(1):76-87. PubMed ID: 17706463
[TBL] [Abstract][Full Text] [Related]
49. Endoplasmic Reticulum Stress Contributes to Mitochondrial Exhaustion of CD8
Hurst KE; Lawrence KA; Essman MT; Walton ZJ; Leddy LR; Thaxton JE
Cancer Immunol Res; 2019 Mar; 7(3):476-486. PubMed ID: 30659052
[TBL] [Abstract][Full Text] [Related]
50. Tet2 Inactivation Enhances the Antitumor Activity of Tumor-Infiltrating Lymphocytes.
Lee M; Li J; Li J; Fang S; Zhang J; Vo ATT; Han W; Zeng H; Isgandarova S; Martinez-Moczygemba M; Zhou Y; Sun D; Huang Y
Cancer Res; 2021 Apr; 81(8):1965-1976. PubMed ID: 33589517
[TBL] [Abstract][Full Text] [Related]
51. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
52. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.
Kjaergaard J; Peng L; Cohen PA; Drazba JA; Weinberg AD; Shu S
J Immunol; 2001 Dec; 167(11):6669-77. PubMed ID: 11714839
[TBL] [Abstract][Full Text] [Related]
53. Myeloid Cell-Derived Arginase in Cancer Immune Response.
Grzywa TM; Sosnowska A; Matryba P; Rydzynska Z; Jasinski M; Nowis D; Golab J
Front Immunol; 2020; 11():938. PubMed ID: 32499785
[TBL] [Abstract][Full Text] [Related]
54. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
[TBL] [Abstract][Full Text] [Related]
55. Deleting the mitochondrial respiration negative regulator MCJ enhances the efficacy of CD8
Wu MH; Valenca-Pereira F; Cendali F; Giddings EL; Pham-Danis C; Yarnell MC; Novak AJ; Brunetti TM; Thompson SB; Henao-Mejia J; Flavell RA; D'Alessandro A; Kohler ME; Rincon M
Nat Commun; 2024 May; 15(1):4444. PubMed ID: 38789421
[TBL] [Abstract][Full Text] [Related]
56. Anti-VEGF Treatment Enhances CD8
de Almeida PE; Mak J; Hernandez G; Jesudason R; Herault A; Javinal V; Borneo J; Kim JM; Walsh KB
Cancer Immunol Res; 2020 Jun; 8(6):806-818. PubMed ID: 32238381
[TBL] [Abstract][Full Text] [Related]
57. Plexin-A4 Mediates Cytotoxic T-cell Trafficking and Exclusion in Cancer.
Celus W; Oliveira AI; Rivis S; Van Acker HH; Landeloos E; Serneels J; Cafarello ST; Van Herck Y; Mastrantonio R; Köhler A; Garg AD; Flamand V; Tamagnone L; Marine JC; Di Matteo M; Costa BM; Bechter O; Mazzone M
Cancer Immunol Res; 2022 Jan; 10(1):126-141. PubMed ID: 34815265
[TBL] [Abstract][Full Text] [Related]
58. The Inhibitory Signaling Receptor Protocadherin-18 Regulates Tumor-Infiltrating CD8
Frey AB
Cancer Immunol Res; 2017 Oct; 5(10):920-928. PubMed ID: 28874354
[TBL] [Abstract][Full Text] [Related]
59. Systemic DC Activation Modulates the Tumor Microenvironment and Shapes the Long-Lived Tumor-Specific Memory Mediated by CD8+ T Cells.
Shimizu K; Yamasaki S; Shinga J; Sato Y; Watanabe T; Ohara O; Kuzushima K; Yagita H; Komuro Y; Asakura M; Fujii S
Cancer Res; 2016 Jul; 76(13):3756-66. PubMed ID: 27371739
[TBL] [Abstract][Full Text] [Related]
60. mTORC1 and mTORC2 selectively regulate CD8⁺ T cell differentiation.
Pollizzi KN; Patel CH; Sun IH; Oh MH; Waickman AT; Wen J; Delgoffe GM; Powell JD
J Clin Invest; 2015 May; 125(5):2090-108. PubMed ID: 25893604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
